Table of Content

1 Middle East Molecular Diagnostics Market
1.1 Product Definition
1.1.1 Inclusion and Exclusion
1.2 Market Overview
1.3 Historical Perspective
1.4 Significant Technologies
1.5 Classification of Molecular Diagnostics
1.6 Future Potential

2 Industry Insights
2.1 Patent Analysis
2.1.1 Patent Filing Trend
2.2 Legal Requirements
2.2.1 Legal Requirements and Framework in the U.S.
2.2.2 U.S. FDA Regulations

3 Competitive Landscape
3.1 Competitive Landscape
3.1.1 Acquisitions
3.1.2 Synergistic Activities
3.1.3 Product Launches and Upgradations
3.1.4 Business Expansion

4 Market Dynamics
4.1 Market Dynamics
4.1.1 Impact Analysis
4.1.2 Market Drivers
4.1.2.1 Increasing Prevalence of Infectious Diseases and Various Types of Cancer in the Middle East
4.1.2.2 Increase in Awareness and Acceptance of Personalized Medicines in the Middle East
4.1.2.3 Significant External Funding for Executing Research and Development Exercises
4.1.3 Market Restraints
4.1.3.1 Uncertain Reimbursement Scenario
4.1.3.2 Lack of High-Complexity Testing Centers in the Middle East
4.1.4 Market Opportunities
4.1.4.1 Massive Scope for Adoption of Molecular Diagnostics
4.1.4.2 Rise of Next-Generation Ultrasensitive Molecular Diagnostics
4.1.4.3 Novel Revenue Streams
4.2 COVID-19 Impact on Middle East Molecular Diagnostics Market
4.2.1 Impact on Market Size
4.2.2 Impact on Molecular Diagnostic Practices

5 Middle East Molecular Diagnostics Market, by Products, $Million, 2021 - 2031
5.1 Overview
5.1.1 Systems
5.1.2 Kits and Consumables
5.1.3 Software and Other Products

6 Middle East Molecular Diagnostics Market, by Testing Location, $Million, 2021 - 2031
6.1 Overview
6.1.1 Laboratory Testing
6.1.2 Point-of-Care Testing

7 Middle East Molecular Diagnostics Market, by Technology, $Million, 2021 - 2031
7.1 Overview
7.1.1 Polymerase Chain Reaction (PCR)
7.1.2 Next-Generation Sequencing
7.1.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
7.1.4 Microarray
7.1.5 In-Situ Hybridization (ISH)
7.1.6 Immunohistochemistry (IHC)
7.1.7 Other Technologies

8 Middle East Molecular Diagnostics Market, by Application, $Million, 2021 - 2031
8.1 Overview
8.1.1 Core Molecular Diagnostics
8.1.2 Reproductive Genetics
8.1.3 Companion Diagnostics (CDx)
8.1.4 Liquid Biopsy
8.1.5 Other Applications

9 Middle East Molecular Diagnostics Market, by End User, $Million, 2021 - 2031
9.1 Overview
9.1.1 Hospitals
9.1.2 Diagnostic Centers
9.1.3 Out-Patient Clinics/General Practitioners
9.1.4 Research Laboratories
9.1.5 Other End Users

10 Middle East molecular diagnostics Market, by Country, $Million, 2020-2031
10.1 Overview
10.1.1 Kingdom of Saudi Arabia (KSA)
10.1.2 Israel
10.1.3 United Arab Emirates (U.A.E.)
10.1.4 Egypt
10.1.5 Iran
10.1.6 Qatar
10.1.7 Rest-of-the-Middle East

11 Market - Competitive Benchmarking & Company Profiles
11.1 Overview
11.2 Abbott.
11.2.1 Company Overview
11.2.2 Role of Abbott. in the Middle East Molecular Diagnostics Market
11.2.3 Key Competitors of the Company
11.2.4 Key Customers of the Company
11.2.5 Business Strategies
11.2.6 Financials
11.2.7 Key Insights about Financial Health of the Company
11.2.8 SWOT Analysis
11.3 Agilent Technologies, Inc.
11.3.1 Company Overview
11.3.2 Role of Agilent Technologies, Inc. in the Middle East Molecular Diagnostics Market
11.3.3 Key Competitors of the Company
11.3.4 Key Customers of the Company
11.3.5 Business Strategies
11.3.6 Corporate Strategies:
11.3.7 Financials
11.3.8 Key Insights about Financial of the Company
11.3.9 SWOT Analysis
11.4 bioM?rieux SA
11.4.1 Company Overview
11.4.2 Role of bioM?rieux SA in the Middle East Molecular Diagnostics Market
11.4.3 Key Competitors of the Company
11.4.4 Key Customers of the Company
11.4.5 Business Strategies
11.4.6 Financials
11.4.7 Key Insights about the Financial Health of the Company
11.4.8 SWOT Analysis
11.5 BD.
11.5.1 Company Overview
11.5.2 Role of BD. in the Middle East Molecular Diagnostics Market
11.5.3 Key Competitors of the Company
11.5.4 Key Customers of the Company
11.5.5 Business Strategies
11.5.6 Financials
11.5.7 Key Insights about Financial Health of the Company
11.5.8 SWOT Analysis
11.6 Babirus Medical Equipment LLC
11.6.1 Company Overview
11.6.2 Role of Babirus Medical Equipment Trading LLC in the Middle East Molecular Diagnostics Market
11.6.3 Key Competitors of the Company
11.6.4 Key Customers of the Company
11.6.5 Business Strategies
11.6.6 SWOT Analysis
11.7 Bio-Rad Laboratories, Inc.
11.7.1 Company Overview
11.7.2 Role of Bio-Rad Laboratories, Inc. in the Middle East Molecular Diagnostics Market
11.7.3 Key Competitors of the Company
11.7.4 Key Customers of the Company
11.7.5 Business Strategies
11.7.5.1 Corporate Strategies
11.7.6 Financials
11.7.7 Key Insights about Financial Health of the Company
11.7.8 SWOT Analysis
11.8 Danaher.
11.8.1 Company Overview
11.8.2 Role of Danaher. in the Middle East Molecular Diagnostics Market
11.8.3 Key Competitors of the Company
11.8.4 Key Customers of the Company
11.8.5 Business Strategies
11.8.6 Corporate Strategies
11.8.7 Financials
11.8.8 Key Insights about Financial Health of the Company
11.8.9 SWOT Analysis
11.9 F. Hoffmann-La Roche Ltd.
11.9.1 Company Overview
11.9.2 Role of F. Hoffmann-La Roche Ltd. in the Middle East Molecular Diagnostics Market
11.9.3 Key Competitors of the Company
11.9.4 Key Customers of the Company
11.9.5 Business Strategies
11.9.6 Corporate Strategies
11.9.7 Financials
11.9.8 Key Insights about Financial Health of the Company
11.9.9 SWOT Analysis
11.10 Guardant Health
11.10.1 Company Overview
11.10.2 Role of Guardant Health in the Middle East Molecular Diagnostics Market
11.10.3 Key Competitors of the Company
11.10.4 Key Customers of the Company
11.10.5 Corporate Strategies
11.10.6 Financials
11.10.7 Key Insights about Financial Health of the Company
1.1.1 SWOT Analysis
11.11 Illumina, Inc.
11.11.1 Company Overview
11.11.2 Role of Illumina, Inc. in the Middle East Molecular Diagnostics Market
11.11.3 Key Competitors of the Company
11.11.4 Key Customers of the Company
11.11.5 Corporate Strategies
11.11.6 Financials
11.11.7 Key Insights about the Financial Health of the Company
11.11.8 SWOT Analysis
11.12 QIAGEN N.V.
11.12.1 Company Overview
11.12.2 Role of QIAGEN N.V. in the Middle East Molecular Diagnostics Market
11.12.3 Key Competitors of the Company
11.12.4 Key Customers of the Company
11.12.5 Corporate Strategies
11.12.6 Key Insights about Financial Health of the Company
11.12.7 SWOT Analysis
11.13 Thermo Fisher Scientific Inc.
11.13.1 Company Overview
11.13.2 Role of Thermo Fisher Scientific Inc. in the Middle East Molecular Diagnostics Market
11.13.3 Key Competitors of the Company
11.13.4 Key Customers of the Company
11.13.5 Business Strategies
11.13.6 Financials
11.13.7 Key Insights about Financial Health of the Company
11.13.8 SWOT Analysis
List of Tables
Table 1: COVID-19 Impact on Middle East Molecular Diagnostics Market
List of Figures
Figure 1: Middle East Molecular Diagnostics Market-Market Dynamics
Figure 2: Share of Key Market Strategies and Developments, January 2017-September 2021
Figure 3: Middle East Molecular Diagnostics Market Snapshot, $Million, 2020-2031
Figure 4: Middle East Molecular Diagnostics Market (by Product), $Million, 2020 Vs. 2031
Figure 5: Middle East Molecular Diagnostics Market (by Technology), $Million, 2020 Vs. 2031
Figure 6: Middle East Molecular Diagnostics Market (by Application), $Million, 2020 Vs. 2031
Figure 7: Middle East Molecular Diagnostics Market (by End User), $Million, 2020 Vs. 2031
Figure 8: Middle East Molecular Diagnostics Market Research Methodology
Figure 9: Middle East Molecular Diagnostics Market: Segmentation
Figure 10: Role of Diagnostics in Healthcare
Figure 11: Evolution of Molecular Diagnostics
Figure 12: Classification of Molecular Diagnostics
Figure 13: Year-Wise Analysis of Patents Related to Molecular Diagnostics, January 2019-October 2021
Figure 14: Share of Key Developments and Strategies, January 2017-September 2021
Figure 15: Share of Acquisitions (by Company), January 2017-September 2021
Figure 16: Share of Synergistic Activities (by Company), January 2017-September 2021
Figure 17: Share of Product Launches and Upgradations (by Company), January 2017-September 2021
Figure 18: Share of Business Expansion (by Company), July 2017-August 2021
Figure 19: Middle East Molecular Diagnostics Market - Market Dynamics
Figure 20: Rate of Cancer Incidence and Death in 2020
Figure 21: Personalized Care for Cancer Patients
Figure 22: Impact of COVID-19 on Middle East Molecular Diagnostics Market
Figure 23: Share of Middle East Molecular Diagnostics Market (by Product), $Million, 2020 and 2031
Figure 24: Middle East Molecular Diagnostics Market (Systems), $Million, 2020-2031
Figure 25: General Workflow of a Molecular Diagnostic Kit
Figure 26: Middle East Molecular Diagnostics Market (Kits and Consumables), $Million, 2020-2031
Figure 27: Aspects of Software Development
Figure 28: Middle East Molecular Diagnostics Market (Software and Other Products), $Million, 2020-2031
Figure 29: Middle East Molecular Diagnostics Market (by Testing Location)
Figure 30: Share of Middle East Molecular Diagnostics Market (by Testing Location), $Million, 2020 and 2031
Figure 31: Middle East Molecular Diagnostics Market (Laboratory Testing), $Million, 2020-2031
Figure 32: Middle East Molecular Diagnostics Market (Point-of-Care Testing), $Million, 2020-2031
Figure 33: Share of Middle East Molecular Diagnostics Market (by Technology), $Million, 2020 and 2031
Figure 34: Middle East Molecular Diagnostics Market (Polymerase Chain Reaction), $Million, 2020-2031
Figure 35: Middle East Molecular Diagnostics Market (Next-Generation Sequencing), $Million, 2020-2031
Figure 36: Middle East Molecular Diagnostics Market (Isothermal Nucleic Acid Amplification Technology), $Million, 2020-2031
Figure 37: Middle East Molecular Diagnostics Market (Microarray), $Million, 2020-2031
Figure 38: Middle East Molecular Diagnostics Market (ISH), $Million, 2020-2031
Figure 39: Middle East Molecular Diagnostics Market (IHC), $Million, 2020-2031
Figure 40: Middle East Molecular Diagnostics Market (Other Technologies), $Million, 2020-2031
Figure 41: Middle East Molecular Diagnostics Market (by Application), $Million, 2020 and 2031
Figure 42: Middle East Molecular Diagnostics Market (Core Molecular Diagnostics), $Million, 2020-2031
Figure 43: Middle East Molecular Diagnostics Market (Reproductive Genetics), $Million, 2020-2031
Figure 44: Middle East Molecular Diagnostics Market (Companion Diagnostics), $Million, 2020-2031
Figure 45: Middle East Molecular Diagnostics Market (Liquid Biopsy), $Million, 2020-2031
Figure 46: Middle East Molecular Diagnostics Market (Other Applications), $Million, 2020-2031
Figure 47: Share of Middle East Molecular Diagnostics Market (by End User), $Million, 2020 and 2031
Figure 48: Middle East Molecular Diagnostics Market (Hospitals), $Million, 2020-2031
Figure 49: Middle East Molecular Diagnostics Market (Diagnostic Centers), $Million, 2020-2031
Figure 50: Middle East Molecular Diagnostics Market (Out-Patient Clinics/General Practitioners), $Million, 2020-2031
Figure 51: Middle East Molecular Diagnostics Market (Research Laboratories), $Million, 2020-2031
Figure 52: Middle East Molecular Diagnostics Market (Other End Users), $Million, 2020-2031
Figure 53: Middle East Molecular Diagnostics Market (by Country), $Million, 2020-2031
Figure 54: Middle East Molecular Diagnostics Market (by Country), 2021 and 2031
Figure 55: Kingdom of Saudi Arabia Diagnostics Market $Million, 2020-2031
Figure 56: Israel Molecular Diagnostics Market, $Million, 2020-2031
Figure 57: U.A.E. Molecular Diagnostics Market, $Million, 2020-2031
Figure 58: Egypt Molecular Diagnostics Market, $Million, 2020-2031
Figure 59: Iran Molecular Diagnostics Market, $Million, 2020-2031
Figure 60: Qatar Molecular Diagnostics Market, $Million, 2020-2031
Figure 61: Rest-of-the-Middle East Molecular Diagnostics Market, $Million, 2020-2031
Figure 62: Total Number of Companies Profiled
Figure 63: Abbott.: Overall Product Portfolio
Figure 64: Abbott.: Overall Financials, 2019-2021
Figure 65: Abbott.: Revenue (by Segment), 2019-2021
Figure 66: Abbott.: Revenue (by Region), 2019-2021
Figure 67: Abbott.: R&D Expenditure, 2019-2021
Figure 68: Abbott.: SWOT Analysis
Figure 69: Agilent Technologies, Inc.: Overall Product Portfolio
Figure 70: Agilent Technologies, Inc.: Overall Financials, 2019-2021
Figure 71: Agilent Technologies, Inc.: Revenue (by Segment), 2019-2021
Figure 72: Agilent Technologies, Inc.: Revenue (by Region), 2019-2021
Figure 73: Agilent Technologies, Inc.: R&D Expenditure, 2019-2021
Figure 74: Agilent Technologies, Inc.: SWOT Analysis
Figure 75: bioM?rieux SA: Product Portfolio
Figure 76: bioM?rieux SA: Overall Financials, $Million, 2019-2021
Figure 77: bioM?rieux SA: Revenue (by Segment), $Million, 2019-2021
Figure 78: bioM?rieux SA: Revenue (by Region), $Million, 2019-2021
Figure 79: bioM?rieux SA: R&D Expenditure, $Million, 2019-2021
Figure 80: bioM?rieux SA: SWOT Analysis
Figure 81: BD.: Overall Product Portfolio
Figure 82: BD.: Overall Financials, 2019-2021
Figure 83: BD.: Revenue (by Segment), 2019-2021
Figure 84: BD.: Revenue (by Region), 2019-2021
Figure 85: BD.: R&D Expenditure, 2019-2021
Figure 86: BD.: SWOT Analysis
Figure 87: Babirus Medical Equipment Trading LLC: Overall Product Portfolio
Figure 88: Babirus Medical Equipment Trading LLC: SWOT Analysis
Figure 89: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 90: Bio-Rad Laboratories, Inc.: Overall Financials, 2019-2021
Figure 91: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2019-2021
Figure 92: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2019-2021
Figure 93: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2019-2021
Figure 94: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 95: Danaher.: Overall Product Portfolio
Figure 96: Danaher.: Overall Financials, 2019-2021
Figure 97: Danaher.: Revenue (by Segment), 2019-2021
Figure 98: Danaher.: Revenue (by Region), 2019-2021
Figure 99: Danaher.: R&D Expenditure, 2019-2021
Figure 100: Danaher.: SWOT Analysis
Figure 101: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 102: F. Hoffmann-La Roche Ltd: Overall Financials, 2019-2021
Figure 103: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2019-2021
Figure 104: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2019-2021
Figure 105: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2019-2021
Figure 106: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 107: Guardant Health: Overall Product Portfolio
Figure 108: Guardant Health: Overall Financials, 2018-2020
Figure 109: Guardant Health: Revenue (by Segment), 2018-2020
Figure 110: Guardant Health: R&D Expenditure, 2018-2020
Figure 111: Guardant Health: SWOT Analysis
Figure 112: Illumina, Inc.: Product Portfolio
Figure 113: Illumina, Inc.: Overall Financials, $Million, 2019-2021
Figure 114: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 115: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 116: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 117: Illumina, Inc.: SWOT Analysis
Figure 118: QIAGEN N.V.: Overall Product Portfolio
Figure 119: QIAGEN N.V.: Overall Financials, 2019-2021
Figure 120: QIAGEN N.V.: Revenue (by Segment), 2019-2021
Figure 121: QIAGEN N.V.: Revenue (by Region), 2019-2021
Figure 122: QIAGEN N.V.: R&D Expenditure, 2019-2021
Figure 123: QIAGEN N.V.: SWOT Analysis
Figure 124: Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 125: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
Figure 126: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), $Million, 2019-2021
Figure 127: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
Figure 128: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
Figure 129: Thermo Fisher Scientific Inc.: SWOT Analysis